The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 3, 2011, Pages 386-393

  Liu, Yuping ^a   She, Miaoqin ^a   Wu, Zhicong ^a   Dai, Renke ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

cytochromes P450; Inhibition; ketoconazole; paclitaxel; UGT1A1; UGT1A4

Indexed keywords

ALPHA NAPHTHOFLAVONE; AMFEBUTAMONE; CHLORZOXAZONE; CLOMETHIAZOLE; COUMARIN; CYCLOSPORIN A; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; DICLOFENAC; FURAFYLLINE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 2B10; GLUCURONOSYLTRANSFERASE 2B7; KETOCONAZOLE; MEPHENYTOIN; MIDAZOLAM; OLEANDOMYCIN; OMEPRAZOLE; PACLITAXEL; PHENACETIN; QUINIDINE; SULFAPHENAZOLE; TESTOSTERONE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; GLUCURONIDATION; HUMAN; IC 50; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; ENZYME INHIBITORS; GLUCURONOSYLTRANSFERASE; HUMANS; MOLECULAR STRUCTURE; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 79955568092     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2010.518965     Document Type: Article

References (31)

1. Hasler JA. Pharmacogenetics of cytochromes P450. Mol Aspects Med 1999;20:12-24, 5-137.
2. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI. Structural and functional studies of UDPglucuronosyltransferases. Drug Metab Rev 1999;31:817-899.
3. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6- glucuronide, a potent mu agonist. Life Sci 1987;41:2845-2849.
4. Radominska-Pandya A, Bratton S, Little JM. A historical overview of the heterologous expression of mammalian UDPglucuronosyltransferase isoforms over the past twenty years. Curr Drug Metab 2005;6:141-160. (Pubitemid 40394342)
5. Terrier N, Benoit E, Senay C, Lapicque F, Radominska-Pandya A, Magdalou J, Fournel-Gigleux S. Human and rat liver UDPglucuronosyltransferases are targets of ketoprofen acylglucuronide. Mol Pharmacol 1999;56:226-234. (Pubitemid 29309832)
6. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 2003;25:1-16. (Pubitemid 36139819)
7. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridinediphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000;16:297-306.
8. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003;3:136-158. (Pubitemid 36850156)
9. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006;34:191-197. (Pubitemid 43042661)
10. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002;72:685-691. (Pubitemid 36021007)
11. Benbrik E, Chariot P, Bonavaud S, Ammi-Saïd M, Frisdal E, Rey C, Gherardi R, Barlovatz-Meimon G. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997;149:19-25. (Pubitemid 27196376)
12. Trapnell CB, Klecker RW, Jamis-Dow C, Collins JM. Glucuronidation of 3′OElig;-azido-3′OElig;-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob Agents Chemother 1998;42:1592-1596. (Pubitemid 28311547)
13. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, Bélanger A. 3′OElig;-azido-3′OElig;-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28:497-502. (Pubitemid 30238507)
14. Nguyen N, Tukey RH. Baculovirus-directed expression of rabbit UDP-glucuronosyltransferases in Spodoptera frugiperda cells. Drug Metab Dispos 1997;25:745-749. (Pubitemid 27259975)
15. Yueh MF, Nguyen N, Famourzadeh M, Strassburg CP, Oda Y, Guengerich FP, Tukey RH. The contribution of UDP-glucuronosyltransferase 1A9 on CYP1A2-mediated genotoxicity by aromatic and heterocyclic amines. Carcinogenesis 2001;22:943-950. (Pubitemid 32514962)
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
17. Yao M, Zhu M, Sinz MW, Zhang H, Humphreys WG, Rodrigues AD, Dai R. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. J Pharm Biomed Anal 2007;44:211-223. (Pubitemid 46551606)
18. Soars MG, Mattiuz EL, Jackson DA, Kulanthaivel P, Ehlhardt WJ, Wrighton SA. Biosynthesis of drug glucuronides for use as authentic standards. J Pharmacol Toxicol Methods 2002;47:161-168. (Pubitemid 36287356)
19. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 2000;28:560-566. (Pubitemid 30238515)
20. Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, Fedeli O, Rival M, Bourrie M, Guillou F, Maurel P, Fabre G. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos 2008;36:851-862. (Pubitemid 351574882)
21. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 2004;32:413-423. (Pubitemid 38420275)
22. King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001;61:49-53. (Pubitemid 32409686)
23. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, Wrighton SA. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 2002;30:1266-1273. (Pubitemid 35265835)
24. Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B. In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 2009;67:445-454.
25. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-832. (Pubitemid 36759050)
26. Maresca A, Temperini C, Vu H, Pham NB, Poulsen SA, Scozzafava A, Quinn RJ, Supuran CT. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057-3062.
27. Maresca A, Temperini C, Pochet L, Masereel B, Scozzafava A, Supuran CT. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010;53:335-344.
28. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 1986;30:206-210. (Pubitemid 16038748)
29. Chu Z, Chen JS, Liau CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner ER, Figg WD, Sparreboom A. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs 2008;19:275-281.
30. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004;32:647-660. (Pubitemid 38668158)
31. Tang C, Lin Y, Rodrigues AD, Lin JH. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab Dispos 2002;30:648-654. (Pubitemid 34579097)